Maze Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeAug 17 →InsidersNo open-market buys. 5 insiders sold $15.9M, 55 of 57 sales on a 10b5-1 plan.→HoldersFrazier Life Sciences 9.1%TRV GP IV 8.1%ARCH Venture 7.4%→Financing →PeersClosest companies: INBX, KYMR, IMNM→
From the filings
Figures
- Revenue
- $2.5Mlast 12 months
- Net income
- −$133.6Mlast 12 months
- Operating cash flow
- −$121.5Mlast 12 months
- Cash and equivalents
- $202.6Mat the last balance sheet
- Total debt
- $39.0Mat the last balance sheet
- Shares outstanding
- 55.5M shareson issue